Indication
Add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Medicine details
- Medicine name:
- mepolizumab (Nucala)
- SMC ID:
- SMC2765
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Publication due date:
- 12 May 2025